1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W739812
    Carboxy finasteride
    Inhibitor
    Carboxy finasteride is a metabolite of the 5α-reductase inhibitor Finasteride (HY-13635). Finasteride is biotransformed by cytochrome P450 (CYP3A4) and is successively oxidized to Hydroxy finasteride and Carboxy finasteride. Carboxy finasteride is the major metabolite in urine, while Hydroxy finasteride is the major metabolite in plasma.
    Carboxy finasteride
  • HY-B1202R
    Alrestatin (Standard)
    Inhibitor
    Alrestatin (Standard) is the analytical standard of Alrestatin. This product is intended for research and analytical applications. 0
    Alrestatin (Standard)
  • HY-176164
    ALR2-IN-6
    Inhibitor
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy.
    ALR2-IN-6
  • HY-129685
    M79175
    Inhibitor
    M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy.
    M79175
  • HY-N0310R
    Soyasaponin Bb (Standard)
    Inhibitor
    Soyasaponin Bb (Standard) is the analytical standard of Soyasaponin Bb (HY-N0310). This product is intended for research and analytical applications. Soyasaponin Bb is an orally active, covalent inducer of heme oxygenase HO-1 and an inhibitor of aldose reductase AKR1B1. Soyasaponin Bb can regulate oxidative stress pathways, enhance antioxidant capacity, reduce reactive oxygen species (ROS) generation, and inhibit lipid peroxidation and hepatocyte apoptosis. Soyasaponin Bb improves alcohol-induced hepatocyte membrane damage and liver function abnormalities, and improves Scopolamine (HY-N0296)-induced memory impairment. Soyasaponin Bb has antioxidant, hepatoprotective, and neuroprotective activities.
    Soyasaponin Bb (Standard)
  • HY-B1392A
    Esmolol
    Inhibitor
    Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers.
    Esmolol
  • HY-162758
    ALR2-IN-5
    Inhibitor
    ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes.
    ALR2-IN-5
  • HY-N0102R
    Isoliquiritigenin (Standard)
    Inhibitor
    Isoliquiritigenin (Standard) is the analytical standard of Isoliquiritigenin. This product is intended for research and analytical applications. Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
    Isoliquiritigenin (Standard)
  • HY-161472
    Aldose reductase-IN-7
    Inhibitor
    Aldose reductase-IN-7 (Compound 6k) targets Aldose reductase. Aldose reductase-IN-7 exhibits potent enzyme inhibitory activity (Ki = 0.186 ± 0.020 μM), showing superiority to Epalrestat (HY-66009), which is currently in clinical use. Aldose reductase-IN-7 is less cytotoxic and possesses potent anticancer activity.
    Aldose reductase-IN-7
  • HY-116600
    AL-4114
    Inhibitor
    AL-4114 is an aldose reductase inhibitor which can be utilized in research related to the prevention of diabetic cataractogenesis.
    AL-4114
  • HY-119842
    ALO1567
    Inhibitor
    ALO1567 (AL1567) is an orally available aldose reductase inhibitor with an IC50 of 27 nM for rat lens aldose reductase. ALO1567 can be used in the research of diabetes.
    ALO1567
  • HY-W715538
    Rhetsinine
    Inhibitor
    Rhetsinine is an aldose reductase inhibitor isolated from Evodia rutaecarpa, exhibiting an IC50 value of 24.1 μM. At a concentration of 100 μM, rhetsinine significantly inhibits sorbitol accumulation by 79.3%. This compound shows potential for research in diabetic complications, including diabetic neuropathy and retinopathy.
    Rhetsinine
  • HY-W653944
    Epalrestat-d5
    Inhibitor
    Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
    Epalrestat-d<sub>5</sub>
  • HY-N14450
    Salfredin A7
    Inhibitor
    Salfredin A7 is an aldose reductase inhibitor.
    Salfredin A7
Cat. No. Product Name / Synonyms Application Reactivity